N/A
Completed N=329
A Non Interventional Study To Asses The Safety, Effectiveness And Tolerability Of Quinapril (Acupil®) In An Indian Population
Source: ClinicalTrials.gov NCT00930722 ↗Enrolled (actual)
329
Serious AEs
0.0%
Results posted
May 2011
Primary outcomePrimary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 0 Participants
Summary
This is a prospective, non-interventional, non comparative drug study. The efficacy of Quinapril in Asian population has been evaluated, but specifically in Indian patients the data is sparse. Data in a real world setting in a large population of Indian patients would shed more light on the safety, tolerability and effectiveness of Quinapril in the Indian population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) |
1; 0 | — |
| SECONDARY Change From Baseline in Systolic Blood Pressure (SBP) at Week 12 |
142.16; -9.40 | — |
| SECONDARY Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12 |
86.31; -3.93 | — |
| SECONDARY Change From Baseline in SBP at Week 52 |
— | — |
| SECONDARY Change From Baseline in DBP at Week 52 |
— | — |
| SECONDARY Change From Pre-treatment in SBP at Week 0 |
154.06; -12.49 | — |
| SECONDARY Change From Pre-treatment in DBP at Week 0 |
92.82; -6.74 | — |
| SECONDARY Number of Participants Achieving BP Goal at Week 12 |
78 | — |
| SECONDARY Number of Participants With Achievement of BP Goal at Week 52 |
— | — |
| SECONDARY Duration of Monotherapy With Quinapril |
— | — |
| SECONDARY Mean Daily Dose of Study Medication |
11.28 | — |
| SECONDARY Number of Participants With Preference for add-on Anti-hypertensive Therapy |
321; 1; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients already on therapy with Acupil® for a minimum period of 4 weeks, Evidence of a personally signed and dated informed consent document
Exclusion Criteria
- Patients having a Week 0 visit blood pressure reading of more than 180/110 mm of Hg will not be eligible to participate in the study.
- Women of child bearing age, not willing to use contraceptives, will not be eligible for the study
- Women using oral contraceptives will also not be included in the study
- Patients who have received any drug other than Acupil® as the first prescribed antihypertensive would not be eligible for enrollment into the trial
- Patients having any complication at Week 0 visit which would require more thorough investigations or who required more than one anti-hypertensive drug at the time of initiation of their therapy will not be included in the study
- Patients having any contraindications as per the LPD of Acupil®
Data sourced from ClinicalTrials.gov (NCT00930722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.